Innocrin Pharmaceuticals
Novel, best-in-class oral inhibitors of cyp17 lyase, a validated enzyme target for the treatment.
Launch date
Employees
Market cap
-
Enterprise valuation
€102—153m (Dealroom.co estimates Apr 2015.)
Durham North Carolina (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $8.0m | Debt | |
$28.0m | Series D | ||
| Total Funding | €25.5m | ||